title: Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake.
abstract: Receptors for the Fc fragment of immunoglobulin G (FcγRs) are important molecules not only to mediate and control the effectors' functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery. In humans, three different types of FcγRs, belonging to the Ig gene superfamily, have been identified; FcγRI (cluster of differentiation (CD64), FcγRII (CD32) and FcγRIII (CD16). A wide range of inflammatory and autoimmune diseases, such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by FcγRs. Recent findings supposed that, under certain conditions, FcγRs are involved in the penetration of antibodies into cells and FcγRs constitute one of the main effector mechanisms through which autoantibodies exert their action. In this review, we concentrate on the role of human FcγRs in autoantibodies penetration and summarize the current knowledge on the structure, ligand binding capacity and their role in autoimmunity and pathogenic effect of autoantibodies.
authors.affiliation: Department of Human Anatomy and Histology, Section of Cell Biology, University of Bari Medical School, Bari, Italy.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Lisi
authors.forename: Margherita
authors.initials: M
authors.lastname: Sisto
authors.forename: Dario Domenico
authors.initials: DD
authors.lastname: Lofrumento
authors.forename: Simona
authors.initials: S
authors.lastname: D'Amore
authors.forename: Massimo
authors.initials: M
authors.lastname: D'Amore
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000473:pathology; D001323:Autoantibodies / Q000276:immunology* / Q000378:metabolism*; D005921:Glomerulonephritis / Q000473:pathology; D006801:Humans; D017452:Receptors, IgG / Q000276:immunology* / Q000378:metabolism*; D014657:Vasculitis / Q000473:pathology
chemical_list: D001323:Autoantibodies; D017452:Receptors, IgG
references.citation: Isr Med Assoc J. 2008 Jan;10(1):13-9
references.pmid: 18300564
references.citation: Dig Dis Sci. 2005 Jan;50(1):181-187
references.pmid: 27837389
references.citation: J Gen Virol. 2001 May;82(Pt 5):1137-1145
references.pmid: 11297688
references.citation: J Clin Invest. 2002 Nov;110(10):1549-57
references.pmid: 12438452
references.citation: Arthritis Res Ther. 2007;9(3):R51
references.pmid: 17521421
references.citation: J Autoimmun. 1998 Oct;11(5):547-56
references.pmid: 9802942
references.citation: Experientia. 1979 Jun 15;35(6):763-5
references.pmid: 467580
references.citation: Autoimmun Rev. 2007 Jun;6(6):325-33
references.pmid: 17537376
references.citation: Curr Opin Immunol. 1996 Apr;8(2):199-205
references.pmid: 8725943
references.citation: Cell Biol Toxicol. 1998 Aug;14(4):261-6
references.pmid: 9733281
references.citation: Muscle Nerve. 1999 Aug;22(8):1030-7
references.pmid: 10417783
references.citation: Rheumatol Int. 2008 Jul;28(9):943-8
references.pmid: 18264709
references.citation: Adv Immunol. 1994;57:1-127
references.pmid: 7872156
references.citation: J Neurosci. 2000 May 15;20(10):3552-62
references.pmid: 10804196
references.citation: Clin Exp Immunol. 1999 Mar;115(3):554-60
references.pmid: 10193433
references.citation: No To Shinkei. 1990 Oct;42(10):945-50
references.pmid: 1705127
references.citation: J Immunol. 1979 May;122(5):1855-62
references.pmid: 376727
references.citation: J Am Soc Nephrol. 1996 Jun;7(6):946-54
references.pmid: 8793805
references.citation: Expert Opin Ther Targets. 2005 Feb;9(1):169-90
references.pmid: 15757489
references.citation: Nature. 2000 Jul 20;406(6793):267-73
references.pmid: 10917521
references.citation: J Immunol. 1992 Mar 1;148(5):1471-8
references.pmid: 1311348
references.citation: Environ Health Perspect. 1999 Oct;107 Suppl 5:767-75
references.pmid: 10502543
references.citation: FASEB J. 2004 Jan;18(1):182-4
references.pmid: 14630707
references.citation: Int Immunol. 1999 Apr;11(4):605-15
references.pmid: 10323214
references.citation: J Autoimmun. 1998 Oct;11(5):557-61
references.pmid: 9802943
references.citation: Cell. 1994 Feb 11;76(3):519-29
references.pmid: 8313472
references.citation: Nature. 1979 Jun 21;279(5715):679-85
references.pmid: 221835
references.citation: Circ Res. 1989 Feb;64(2):179-92
references.pmid: 2536302
references.citation: J Autoimmun. 2000 Aug;15(1):15-20
references.pmid: 10936024
references.citation: J Autoimmun. 1998 Oct;11(5):523-33
references.pmid: 9802939
references.citation: Rheumatology (Oxford). 2005 Jun;44(6):729-34
references.pmid: 15757966
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11076-81
references.pmid: 15258288
references.citation: Clin Exp Rheumatol. 2008 Jan-Feb;26(1):89-95
references.pmid: 18328152
references.citation: N Engl J Med. 2003 Oct 16;349(16):1526-33
references.pmid: 14561795
references.citation: Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92
references.pmid: 14561184
references.citation: Scand J Rheumatol. 1990;19(2):123-35
references.pmid: 1692420
references.citation: J Autoimmun. 1998 Oct;11(5):535-8
references.pmid: 9802940
references.citation: Clin Rev Allergy Immunol. 2002 Dec;23(3):279-99
references.pmid: 12402413
references.citation: J Immunol. 2000 Jun 1;164(11):6020-6
references.pmid: 10820286
references.citation: J Invest Dermatol. 2002 Nov;119(5):1074-9
references.pmid: 12445195
references.citation: J Mol Biol. 2000 Jan 14;295(2):213-24
references.pmid: 10623521
references.citation: Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12266-71
references.pmid: 11050246
references.citation: J Immunol. 2001 Mar 15;166(6):3882-9
references.pmid: 11238632
references.citation: J Exp Med. 1989 Aug 1;170(2):481-97
references.pmid: 2526846
references.citation: Nat Struct Biol. 1999 May;6(5):437-42
references.pmid: 10331870
references.citation: J Clin Immunol. 2005 Jan;25(1):1-18
references.pmid: 15742153
references.citation: J Oral Pathol Med. 2007 Oct;36(9):511-23
references.pmid: 17850433